This is supported by the neuroprotective effects of class IIa HDAC inhibition [35,42], which rationalises the further study of class IIa HDAC inhibition in neuroprotective therapy for PD, and in particular the investigation of their effects in models of α-synucleinopathy. Here, HDAC9 is linked to Parkinson disease.